Type of non Hodgkin's lymphoma-Mantle cell lymphoma - Page 3 of 7 Posts on Medivizor
Navigation Menu

Type of non Hodgkin’s lymphoma-Mantle cell lymphoma Posts on Medivizor

Evaluating high-dose cyclophosphamide for patients with hard-to-treat B-cell non-Hodgkin’s lymphoma

Evaluating high-dose cyclophosphamide for patients with hard-to-treat B-cell non-Hodgkin’s lymphoma

Posted by on Jan 12, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of high-dose cyclophosphamide (Cytoxan) for the treatment of relapsed or unresponsive non-Hodgkin’s lymphoma (NHL). This study concluded that high-dose cyclophosphamide was safe and effective for these patients. Some background Chemotherapy regimens remain a standard treatment...

Read More

Trends in outcomes of allogeneic transplantation for elderly patients with non-Hodgkin lymphoma

Trends in outcomes of allogeneic transplantation for elderly patients with non-Hodgkin lymphoma

Posted by on Dec 28, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness of allogeneic stem cell transplants (allo-SCT) in elderly patients with non-Hodgkin’s lymphoma (NHL). This study found that allo-SCT has improved survival outcomes for these patients. Some background Allogeneic stem cell transplantation (allo-SCT) can be highly effective for patients with...

Read More

How effective and safe is acalabrutinib compared to other treatments for patients with mantle cell lymphoma?

How effective and safe is acalabrutinib compared to other treatments for patients with mantle cell lymphoma?

Posted by on Nov 24, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study compared the effectiveness and safety of acalabrutinib (Calquence) to other targeted therapies for patients with mantle cell lymphoma (MCL). The authors found that acalabrutinib was just as safe and more effective for these patients. Some background MCL is a type of non-Hodgkin's lymphoma treated in...

Read More

What factors can predict the success of stem cell transplantation for patients with non-Hodgkin lymphoma?

What factors can predict the success of stem cell transplantation for patients with non-Hodgkin lymphoma?

Posted by on Nov 3, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the risk factors associated with delayed engraftment (DE) in patients who had stem cell transplantation (SCT). The authors found that patients receiving blood transfusions, those with low platelet levels, and those given low numbers of stem cells during SCT were more likely to experience DE. Some background...

Read More

The effect of uric acid levels on the outcomes of patients having an allogeneic stem cell transplant

Posted by on Nov 2, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study aimed to investigate the association of uric acid levels before a stem cell transplant and patient outcomes. This study concluded that high uric acid levels before the transplant led to an increased mortality. Some background Uric acid is a product of metabolic breakdown and is a normal component of urine. It can also be...

Read More

Does stem cell transplantation affect the quality of life of older patients with NHL?

Does stem cell transplantation affect the quality of life of older patients with NHL?

Posted by on Oct 10, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the quality of life reported by elderly patients with non-Hodgkin's lymphoma (NHL) after a stem cell transplant (SCT). The authors concluded that quality of life for these patients was very good following SCT. Some background Autologous SCT is the standard of care in first-line treatment for...

Read More

Searching for patients with relapsed/unresponsive non-Hodgkin lymphoma to test an experimental antibody drug

Posted by on Sep 25, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study is examining the effects of IGM-2323 for certain types of relapsed/unresponsive non-Hodgkin lymphoma. The main outcomes that will be measured are the side effects experienced by patients and the effectiveness of treatment. This trial is recruiting in the United States. The details Non-Hodgkin lymphoma (NHL) is a...

Read More

Evaluating the TLI-ATG conditioning regimen before allogeneic stem cell transplantation in patients with lymphoma or leukemia

Evaluating the TLI-ATG conditioning regimen before allogeneic stem cell transplantation in patients with lymphoma or leukemia

Posted by on Sep 13, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of total lymphoid irradiation and anti-thymocyte globulin (TLI-ATG) conditioning before stem cell transplantation (SCT) in patients with lymphoma or leukemia. This study concluded that this regimen was well-tolerated and effective, especially for patients who had multiple lines of prior...

Read More

Which patients with mantle cell lymphoma may benefit from stem cell therapy?

Which patients with mantle cell lymphoma may benefit from stem cell therapy?

Posted by on Aug 31, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This article reviewed which patients with mantle cell lymphoma benefitted most from a stem cell transplant. Some background Mantle cell lymphoma (MCL) is a rare type of non-Hodgkin's lymphoma. It can be challenging to treat. There is no single standard treatment for patients with MCL. However, for young and fit patients, intensive...

Read More

Can immune profiling help predict outcomes for patients with NHL after a stem cell transplant?

Can immune profiling help predict outcomes for patients with NHL after a stem cell transplant?

Posted by on Aug 25, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study compared the outcomes of filgrastim (Neupogen) treatment with versus without plerixafor (Mozobil) in patients with B-cell non-Hodgkin's lymphoma (NHL) after a stem cell transplant. The authors concluded that certain immune cell biomarkers were associated with poorer long-term survival for these patients. Some...

Read More

Evaluating the safety and effectiveness of the Shingrix vaccine for patients with lymphoma or leukemia

Evaluating the safety and effectiveness of the Shingrix vaccine for patients with lymphoma or leukemia

Posted by on Aug 23, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of the herpes zoster vaccine (Shingrix) in patients with blood cancer who are receiving anti-cancer therapy. This study concluded that the Shingrix vaccine was effective in these patients, with manageable side effects. Some background Shingles is caused by a virus called herpes zoster....

Read More